03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Bimagrumab: Phase II/III data

Top-line data from the double-blind, placebo-controlled, international Phase II/III RESILIENT trial in about 240 patients with sIBM showed that IV bimagrumab missed the primary endpoint. The trial evaluated 3 dose levels of bimagrumab. Novartis said...
03:07 , Apr 22, 2016 |  BC Extra  |  Clinical News

MorphoSys slides on bimagrumab miss

MorphoSys AG (Xetra:MOR) fell EUR 8.62 (17%) to EUR 41.78 on Thursday after bimagrumab ( BYM338) missed the primary endpoint in a Phase II/III trial to treat sporadic inclusion body myositis (sIBM). MorphoSys' partner Novartis...
01:53 , Mar 3, 2016 |  BC Extra  |  Financial News

MorphoSys gains on financial results, outlook

MorphoSys AG (Xetra:MOR) gained EUR 4.01 (11%) to EUR 41.72 on Wednesday after reporting 4Q15 and 2015 financial results, including revenues for the year that came in slightly above its guidance. MorphoSys reported EUR 106.2...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
07:00 , Apr 28, 2014 |  BioCentury  |  Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

Bimagrumab: Phase II/III started

Novartis began a double-blind, placebo-controlled Phase II/III trial to evaluate 3 dose levels of IV bimagrumab in about 240 patients. MorphoSys said the start triggered an undisclosed milestone payment from Novartis under a 2007 deal...